Sera Prognostics, Inc.
SERASera Prognostics, Inc. in brief
Sera Prognostics, Inc. is a listed company in the Diagnostics and Research industry, based in Salt Lake City, Utah, USA. It was founded in 2008. Its market value was $82 M on 30 October 2026, which makes it the 19,475th largest listed company in the world and the 3,626th largest in the USA on this site. In the year to December 2025 it had sales of $0 M and a net loss of $32 M. It employs about 72 people and Zhenya Lindgardt is its chief executive. Its shares trade under the symbol SERA (Nasdaq).
Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.
About Sera Prognostics, Inc.
We are a women’s health company utilizing our proprietary proteomics and bioinformatics platform, and significant data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. Our vision is to become the global leader in high-value women’s health diagnostics. We plan to do this by taking a holistic approach to providing pivotal and actionable information to pregnant women, their physicians, and health care payers to significantly enhance a mother’s pregnancy journey, improve maternal and neonatal health, and reduce health care costs. We believe that our method of combining the disciplines of proteomics and bioinformatics with rigorous clinical testing, data, and economic analysis enables us to provide physicians and expectant mothers with personally insightful, clinically meaningful, and economically impactful information designed to improve the pregnancy experience and outcomes for mothers and babies.
From the company's annual report filed with the US SEC: read the report
Sera Prognostics, Inc. timeline
- 2008
- 🏁· approximateFounded
- 2011
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2021
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 16 July 2021; shares registered for exchange trading on 14 July 2021.
- 2023
- 💰Record revenue of $0 millionFY2023, the highest of the 6 years on record.
Events of Sera Prognostics, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,775 (Jan 2022) · #4,774 (Dec 2022) · #4,332 (Jul 2023) · #3,333 (Jan 2024) · #2,026 (Mar 2026) · #3,568 (Aug 2026) · #3,631 (Sep 2026) · #3,629 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 1024.1×
- Price / book
- 1.1×
- Free cash flow yield
- -32.2%
- Net margin (TTM)
- -41837.5%
- Operating margin
- -45625.0%
- Return on equity
- -44.4%
- Liabilities / assets
- 26.0%
- Revenue growth
- 0.0%
- R&D / revenue
- 16462.5%
- Revenue per employee
- $1 K
- Profit per employee
- $-443 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $0M | 0.0% | $-37M | $-32M | -39912.5% |
| Dec 2024 | $0M | -74.2% | $-37M | $-33M | -41125.0% |
| Dec 2023 | $0M | +14.8% | $-40M | $-36M | -11690.3% |
| Dec 2022 | $0M | +237.5% | $-46M | $-44M | -16366.7% |
| Dec 2021 | $0M | +300.0% | $-35M | $-35M | -43762.5% |
| Dec 2020 | $0M | — | $-18M | $-20M | -99250.0% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-26M | $1M | $-26M | $-0.67 | — |
| Dec 2024 | $-14M | $0M | $-14M | $-0.99 | — |
| Dec 2023 | $-27M | $0M | $-27M | $-1.16 | — |
| Dec 2022 | $-35M | $1M | $-35M | $-1.43 | — |
| Dec 2021 | $-32M | $1M | $-33M | $-2.33 | — |
| Dec 2020 | $-17M | $0M | $-17M | $-12.76 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $0M (+100.0% on a year earlier), net income $-8M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 4, 202610-QQuarterly report · period to Sep 2026
- Nov 4, 20268-KCurrent reportResults of operations
- Aug 19, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure
- Aug 12, 202610-QQuarterly report · period to Jun 2026
- Aug 12, 20268-KCurrent reportResults of operations
- Jun 30, 20268-KCurrent reportDirectors or officers changed
- Jun 4, 20268-KCurrent reportShareholder vote
- Jun 1, 20268-KCurrent reportDirectors or officers changed
- May 6, 202610-QQuarterly report · period to Mar 2026
- May 6, 20268-KCurrent reportResults of operations
- Apr 24, 2026DEF 14AProxy statement
- Mar 18, 202610-KAnnual report · period to Dec 2025
Official filings of Sera Prognostics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $0 M
- Operating income
- $-37 M
- Net income
- $-32 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $102 M
- Total liabilities
- $27 M
- Total equity
- $75 M
As of December-2025
Top 48 institutional investors in Sera Prognostics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Baker Bros. Advisors LP | 5,498,170 | 0 (0.00%) | 13.63% | $11 M | Nov 16, 2026 |
| 2 | Whetstone Capital Advisors, LLC | 3,306,889 | 0 (0.00%) | 8.20% | $7 M | Nov 16, 2026 |
| 3 | Aberdeen Group plc | 2,953,194 | +199,669 (+7.25%) | 7.32% | $6 M | Nov 10, 2026 |
| 4 | PSP Research LLC | 2,396,685 | New | 5.94% | $5 M | Oct 21, 2026 |
| 5 | Vivo Capital, LLC | 1,650,440 | 0 (0.00%) | 4.09% | $3 M | Nov 13, 2026 |
| 6 | Vanguard Capital Management LLC | 1,297,792 | 0 (0.00%) | 3.22% | $3 M | Nov 13, 2026 |
| 7 | Geode Capital Management, LLC | 348,967 | 0 (0.00%) | 0.87% | $1 M | Nov 6, 2026 |
| 8 | Sanders Morris Harris LLC | 314,950 | New | 0.78% | $1 M | Oct 14, 2026 |
| 9 | Captrust Financial Advisors | 306,863 | -228,892 (-42.72%) | 0.76% | $1 M | Nov 12, 2026 |
| 10 | BlackRock, Inc. | 223,374 | +2,005 (+0.91%) | 0.55% | $0 M | Nov 13, 2026 |
| 11 | Vanguard Fiduciary Trust Co | 208,249 | +37,341 (+21.85%) | 0.52% | $0 M | Nov 13, 2026 |
| 12 | AWM Investment Company, Inc. | 207,382 | 0 (0.00%) | 0.51% | $0 M | Nov 13, 2026 |
| 13 | State Street Corp | 124,792 | 0 (0.00%) | 0.31% | $0 M | Nov 12, 2026 |
| 14 | Perigon Wealth Management, LLC | 72,685 | 0 (0.00%) | 0.18% | $0 M | Oct 22, 2026 |
| 15 | Northern Trust Corp | 68,595 | 0 (0.00%) | 0.17% | $0 M | Nov 16, 2026 |
| 16 | Millennium Management LLC | 61,949 | -12,037 (-16.27%) | 0.15% | $0 M | Nov 16, 2026 |
| 17 | Bank of New York Mellon Corp | 60,927 | 0 (0.00%) | 0.15% | $0 M | Nov 5, 2026 |
| 18 | Requisite Capital Management, LLC | 55,648 | 0 (0.00%) | 0.14% | $0 M | Nov 12, 2026 |
| 19 | Bridgeway Capital Management, LLC | 54,856 | -849 (-1.52%) | 0.14% | $0 M | Nov 16, 2026 |
| 20 | Citadel Advisors LLC | 50,271 | +8,860 (+21.40%) | 0.12% | $0 M | Nov 16, 2026 |
| 21 | Empowered Funds, LLC | 50,256 | New | 0.12% | $0 M | Nov 13, 2026 |
| 22 | Ballentine Partners, LLC | 49,664 | 0 (0.00%) | 0.12% | $0 M | Nov 13, 2026 |
| 23 | Morgan Stanley | 48,572 | -2,400 (-4.71%) | 0.12% | $0 M | Nov 13, 2026 |
| 24 | Goldman Sachs Group Inc | 47,974 | +15,433 (+47.43%) | 0.12% | $0 M | Nov 16, 2026 |
| 25 | Twelve Points Wealth Management LLC | 43,388 | 0 (0.00%) | 0.11% | $0 M | Nov 3, 2026 |
All 48 institutional investors: 26 to 48, with who bought and sold →
Mutual funds holding Sera Prognostics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 abrdn Healthcare Investorsabrdn Inc. | 1.38 M | $3 M | 3.9% | 0.18% | +6.3% | Jun 30, 2026 |
| 🇺🇸 abrdn Healthcare Opportunities Fundabrdn Inc. | 1.36 M | $2 M | 3.8% | 0.30% | +8.0% | Jun 30, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 887,016 | $2 M | 2.5% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 380,212 | $1 M | 1.1% | <0.01% | +25% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 172,649 | $0 M | 0.48% | <0.01% | +7.6% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 102,359 | $0 M | 0.29% | 0.01% | +29% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 50,639 | $0 M | 0.14% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 43,469 | $0 M | 0.12% | <0.01% | +3.2% | May 31, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 51,105 | $0 M | 0.14% | 0.06% | +24% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 23,191 | $0 M | 0.07% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 21,836 | $0 M | 0.06% | <0.01% | +109% | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 18,716 | $0 M | 0.05% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 11,848 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 6,968 | $0 M | 0.02% | <0.01% | +30% | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 5,403 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP | 5,101 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 3,288 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 AST Small-Cap Equity PortfolioAST Investment Services, Inc. | 2,450 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 174 | $0 M | <0.01% | <0.01% | +11% | Jul 31, 2026 |
As of Jul 31, 2026
Insider trading at Sera Prognostics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Inglis Tiffany Eul DavisChief Medical Officer | Sell | -8,024 | $2.030 | $16 K | 83,565 | Form 4 |
| filed | Inglis Tiffany Eul DavisChief Medical Officer | Sell | -486 | $2.000 | $972 | 91,589 | Form 4 |
| filed | Zhenya LindgardtChief Executive Officer, Director | Sell | -7,022 | $2.000 | $14 K | 837,848 | Form 4 |
| filed | Benjamin JacksonGeneral Counsel | Sell | -2,190 | $2.000 | $4 K | 159,566 | Form 4 |
| filed | Dyaarl Lee Anderson Jr.Chief Commercial Officer | Sell | -1,800 | $2.000 | $4 K | 76,198 | Form 4 |
| filed | Zhenya LindgardtChief Executive Officer, Director | Sell | -20,139 | $2.000 | $40 K | 844,870 | Form 4 |
| filed | Scott GleasonChief Financial Officer | Grant or award | +117,924 | — | — | 117,924 | Form 4 |
| filed | Joshua PhillipsDirector | Grant or award | +22,426 | — | — | 79,431 | Form 4 |
Markets and events: Sera Prognostics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-2.08 reverse split
Fails to deliver
- : 90 shares at $2.06
- : 1 shares at $2.04
- : 1 shares at $2.03
- : 505 shares at $2.12
- : 66 shares at $1.99
Sera Prognostics, Inc. scorecard#
Passes 2 of the 14 checks that could be worked out: strongest in financial health (1 of 3), weakest in growth (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation1 of 4
Growth0 of 3
Profitability0 of 3
Financial health1 of 3
Shareholder returns0 of 1
Worked out from the statements as filed (sec), the medians of Diagnostics and Research, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Sera Prognostics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 0.1 | 0.1 | 0.3 | 0.3 | 0.1 | 0.0 | |
| Cost of revenue | 0.2 | 0.1 | 0.2 | — | — | — | |
| Research and development | 13 | 15 | 15 | 14 | 11 | 7.8 | |
| Selling and marketing | 6.5 | 5.8 | 8.3 | 15 | 10 | 3.6 | |
| General and administrative | 17 | 16 | 16 | 17 | 14 | 6.6 | |
| Operating expenses | 37 | 37 | 40 | 46 | 35 | 18 | |
| Operating income | −37 | −37 | −40 | −46 | −35 | −18 | |
| Interest expense and finance costs | 0.0 | 0.0 | 0.1 | — | — | — | |
| Other non-operating income (expense) | 4.6 | 3.8 | 3.6 | 1.5 | 1.1 | −0.0 | |
| Income before tax | −32 | −33 | — | — | — | — | |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | |
| Net income attributable to shareholders | −32 | −33 | −36 | −44 | −35 | −20 | |
| Earnings per share, basic | -0.67 | -0.99 | -1.16 | -1.43 | -2.33 | -12.76 | |
| Earnings per share, diluted | -0.67 | -0.99 | -1.16 | -1.43 | -2.33 | -12.76 | |
| Shares, weighted average (basic) | 48 | 33 | 31 | 31 | 15 | 1.6 | |
| Shares, weighted average (diluted) | 48 | 33 | 31 | 31 | 15 | 1.6 | |
| Balance sheet | |||||||
| Cash and cash equivalents | 3.9 | 4.0 | 3.9 | 30 | 59 | 14 | |
| Short-term investments | 35 | 42 | 45 | 53 | 46 | 0 | |
| Receivables | 0.0 | 0.0 | 0.2 | 0.1 | 0.0 | 0.0 | |
| Other current assets | 1.6 | 1.3r | 0.8 | 1.3 | 2.0 | 0.2 | |
| Current assets | 41 | 48 | 61 | 90 | 110 | 14 | |
| Property, plant and equipment | 1.1 | 1.2 | 2.0 | 3.1 | 1.8 | 1.0 | |
| Right-of-use (leased) assets | 2.4 | 0.6 | 1.2 | 1.7 | — | — | |
| Other intangible assets | 0.9 | 1.0 | 0 | — | — | — | |
| Total assets | 102 | 73 | 95 | 116 | 147 | 15 | |
| Accounts payable | 0.9 | 2.0 | 1.0 | 1.5 | 1.2 | 0.4 | |
| Current liabilities | 24 | 25 | 24 | 16 | 8.4 | 11 | |
| Lease liabilities (non-current) | 2.3 | 0 | 0.6 | 1.2 | 0 | — | |
| Total liabilities | 27 | 25 | 25 | 17 | 8.5 | 12 | |
| Retained earnings | −312 | −280 | −247 | −211 | −166 | −131 | |
| Shareholders' equity | 75 | 48 | 70 | 99 | 139 | −126 | |
| Total liabilities and equity | 102 | 73 | 95 | 116 | 147 | 15 | |
| Cash-flow statement | |||||||
| Depreciation and amortization | 0.9 | 0.8 | 0.9 | 0.8 | 0.7 | 0.9 | |
| Share-based compensation | 5.1 | 7.0 | 5.3 | 5.1 | 3.1 | 0.7 | |
| Cash from operating activities | −26 | −14 | −27 | −35 | −32 | −17 | |
| Capital expenditure | −0.7 | −0.1 | −0.1 | −0.8 | −1.3 | −0.1 | |
| Intangible assets bought | 0 | −1.0 | 0 | — | — | — | |
| Cash from investing activities | −29 | 12 | 0.4 | 5.6 | −83 | −0.1 | |
| Debt issued | — | — | — | — | 0 | 1.1 | |
| Debt repaid | — | — | — | 0 | −3.1 | 0 | |
| Shares issued | 54 | — | — | — | — | — | |
| Cash from financing activities | 54 | 2.6 | 0.8 | 0.0 | 160 | 9.2 | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
As of Sep 30, 2026
Events at Sera Prognostics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 3 · Material agreement 1 · Shareholder vote 3 · Results announced 12
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K |
As of Nov 4, 2026
Acquisitions and funding#
6 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Feb 2021 | $100 M | No. 6 | $50 to $250 million | 16 | equity, debt, options | SEC |
| Jul 2019 | $52 M | No. 5 | $50 to $250 million | 28 | equity, debt, options | SEC |
| Jan 2017 | $23 M | No. 4 | $10 to $50 million | 5 | equity | SEC |
| Nov 2014 | $5 M | No. 3 | $2 to $10 million | 15 | equity | SEC |
| May 2014 | $9 M | No. 2 | $2 to $10 million | 15 | equity | SEC |
| Nov 2011 | $10 M | No. 1 | $10 to $50 million | 15 | equity | SEC |
How Sera Prognostics, Inc. compares in Diagnostics and Research
- Market cap$82 M · higher than 25% of 110
- Revenue$0 M · higher than 2% of 123
- Revenue growth0.0% · higher than 31% of 89
- Price / book1.1× · lower than 82% of 84
- FCF yield-32.2% · higher than 15% of 66
Peer comparison · Diagnostics and Research
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Sera Prognostics, Inc.🇺🇸 | $82 M | — | — | 0.0% |
| Thermo Fisher Scientific Inc.🇺🇸 | $253.8 B | 35.9× | 14.9% | +3.9% |
| Danaher Corporation🇺🇸 | $166.7 B | 38.5× | 16.9% | +2.9% |
| WuXi AppTec Co., Ltd.🇨🇳 | $70.4 B | 25.4× | 42.1% | — |
| Natera, Inc.🇺🇸 | $58.7 B | — | -5.7% | +35.9% |
| Siemens Healthineers AG🇩🇪 | $52.8 B | 22.9× | 8.7% | — |
| Lonza Group AG🇨🇭 | $51.9 B | — | -4.2% | — |
| Agilent Technologies, Inc.🇺🇸 | $48.8 B | 33.9× | 19.5% | +6.7% |
| IQVIA Holdings Inc.🇺🇸 | $45.1 B | 32.4× | 8.1% | +5.9% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
How current the figures are
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 21, 2026
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Sera Prognostics, Inc.? Verify and update this profile — free
Show Sera Prognostics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.